Allergy:过敏性鼻炎患者中不同过敏原鼻反应性的共存研究

2020-02-10 AlexYang MedSci原创

过敏性鼻炎(AR)和局部过敏性鼻炎(LAR)分别是通过气源性致敏原的鼻反应性具有和不具有阳性皮刺测试(SPT)来确定的。最近,有研究人员调查了是否两种类型的过敏原特异性反应可以在同一个个体中共存。研究包括了48名具有常年性鼻炎症状和只对季节性过敏原阳性SPT的患者(差异组),该组连续的进行季节性过敏原(NAC-S)和常年性过敏原(NAC-P)鼻过敏原挑战(NAC)。研究人员在NACs前后收集了鼻灌

过敏性鼻炎(AR)和局部过敏性鼻炎(LAR)分别是通过气源性致敏原的鼻反应性具有和不具有阳性皮刺测试(SPT)来确定的。最近,有研究人员调查了是否两种类型的过敏原特异性反应可以在同一个个体中共存。

研究包括了48名具有常年性鼻炎症状和只对季节性过敏原阳性SPT的患者(差异组),该组连续的进行季节性过敏原(NAC-S)和常年性过敏原(NAC-P)鼻过敏原挑战(NAC)。研究人员在NACs前后收集了鼻灌洗液来测量嗜酸细胞阳离子蛋白(ECP)。之后,研究人员在10名差异组患者、6名季节过敏性鼻炎(SAR)、8名常年局部过敏性鼻炎(LAR)、6名非过敏性鼻炎(NAR)和6名健康对照(HC)个体中进行了季节和/或常年过敏原的嗜碱细胞激活测试(BAT)。研究发现,差异组所有患者在NAC-S中均为阳性,其中41名(85%)在NAC-P中也为阳性(组A)。相反,7名患者在NAC-P测试中为阴性(组B)。在组A中,NAC-P后鼻灌洗液的ECP增加(p=0.004),而组B中没有出现ECP增加。季节过敏原BAT在SAR和组A案例中均为阳性,而常年过敏原BAT在LAR和组A案例中的阳性率分别为37.5%和60%。另外,所有NAR和HC受试者BAT测试均为阴性。

最后,研究人员指出,他们的研究表明了阳性和非阳性SPT气源性致敏原鼻反应性在同一个患者中是可以共存的。因此,研究人员为该鼻炎类型提出了一个新的双重过敏性鼻炎的概念。

原始出处:

Eguiluz-Gracia I, Fernandez-Santamaria R, Testera-Montes A et al. Coexistence of Nasal Reactivity to Allergens with and without IgE-sensitization in Patients with Allergic Rhinitis. Allergy. 29 Jan 2020.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2142227, encodeId=5fc9214222e34, content=阳性和非阳性SPT气源性致敏原鼻反应性在同一个患者中是可以共存的, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65724176436, createdName=13d0179fm99暂无昵称, createdTime=Sun Jun 11 16:30:03 CST 2023, time=2023-06-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2022837, encodeId=120e202283ee5, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Oct 22 04:07:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047224, encodeId=323f204e224a2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 31 04:07:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329336, encodeId=7fb31329336d3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442629, encodeId=2588144262938, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2023-06-11 13d0179fm99暂无昵称 来自山西省

    阳性和非阳性SPT气源性致敏原鼻反应性在同一个患者中是可以共存的

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2142227, encodeId=5fc9214222e34, content=阳性和非阳性SPT气源性致敏原鼻反应性在同一个患者中是可以共存的, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65724176436, createdName=13d0179fm99暂无昵称, createdTime=Sun Jun 11 16:30:03 CST 2023, time=2023-06-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2022837, encodeId=120e202283ee5, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Oct 22 04:07:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047224, encodeId=323f204e224a2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 31 04:07:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329336, encodeId=7fb31329336d3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442629, encodeId=2588144262938, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2142227, encodeId=5fc9214222e34, content=阳性和非阳性SPT气源性致敏原鼻反应性在同一个患者中是可以共存的, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65724176436, createdName=13d0179fm99暂无昵称, createdTime=Sun Jun 11 16:30:03 CST 2023, time=2023-06-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2022837, encodeId=120e202283ee5, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Oct 22 04:07:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047224, encodeId=323f204e224a2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 31 04:07:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329336, encodeId=7fb31329336d3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442629, encodeId=2588144262938, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2142227, encodeId=5fc9214222e34, content=阳性和非阳性SPT气源性致敏原鼻反应性在同一个患者中是可以共存的, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65724176436, createdName=13d0179fm99暂无昵称, createdTime=Sun Jun 11 16:30:03 CST 2023, time=2023-06-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2022837, encodeId=120e202283ee5, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Oct 22 04:07:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047224, encodeId=323f204e224a2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 31 04:07:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329336, encodeId=7fb31329336d3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442629, encodeId=2588144262938, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-02-12 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=2142227, encodeId=5fc9214222e34, content=阳性和非阳性SPT气源性致敏原鼻反应性在同一个患者中是可以共存的, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65724176436, createdName=13d0179fm99暂无昵称, createdTime=Sun Jun 11 16:30:03 CST 2023, time=2023-06-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2022837, encodeId=120e202283ee5, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Oct 22 04:07:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047224, encodeId=323f204e224a2, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 31 04:07:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329336, encodeId=7fb31329336d3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442629, encodeId=2588144262938, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Wed Feb 12 04:07:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]

相关资讯

Int J Pharm:CD13特异性配体能够促进苍儿素纳米药物靶向树突细胞来治疗难治性过敏性鼻炎

过敏性鼻炎(AR)的复发由各种不同的未知机制激发。苍耳(Xanthium strumarium L.)是一种传统的民间草药,能够通过多种不同的机制来抑制炎症响应。苍儿素(XT)是一种来源苍耳的生物活性复合物。最近,有研究人员开发了一种高分子纳米微胞(PM),是基于环肽片段(NGR)的一种装载了XT(NGR-XT-PM)的树突细胞(DCs)特异性靶向传输系统,从而使DCs对难治性AR治疗产生抗性。研

Eur Arch Otorhinolaryngol:调控T细胞在过敏性鼻炎中的作用研究

过敏性比亚(AR)是一种lgE介导的鼻部炎症。调控T细胞(Tregs)和炎症细胞因子在过敏性气道炎症中具有关键的作用。最近,有研究人员在AR患者和健康对照中,比较了血液T淋巴细胞亚群水平以及血清和鼻灌洗液中IL-10、IL-17和新蝶呤浓度情况。研究包括了38名患有中度到重度的AR受试者和36名性别和年龄匹配的对照。研究人员利用流式细胞仪对外周血CD3+、CD3+CD4+和CD4+CD25+Fox

J Allergy Clin Immunol:长期暴露于空气污染于鼻炎严重度增加有关

很少有研究调查成年人中长期室外空气污染与鼻炎严重度之间的相关性。最近,有研究人员评估了个体长期暴露于空气污染条件下与鼻炎严重度之间的典型相关性。患有鼻炎的参与者来自2个多中心欧洲群体,总共包括了1408名成年人(平均年龄,52岁;46%为男性,81%来自于欧盟呼吸健康调查)。鼻炎严重度评分均值(第1四分位到第3四分位)为4(2-6)。更多的接触PM10与更严重的鼻炎相关(PM10每增加10 μg/

盘点:过敏性鼻炎研究盘点

过敏性鼻炎主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病。其发生的必要条件有特异性抗原即引起机体免疫反应的物质、特应性个体、特异性抗原与特应型个体二者相遇。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】Eur Respir J:早期经历空气污染和儿童哮喘、

盘点:鼻炎分子机制进展

【1】ORL J Otorhinolaryngol Relat Spec:IL-35能够抑制抑制过敏性鼻炎儿童的Th17响应 之前的研究证明了Th17(辅助性T17细胞)细胞亚群,一种特异的促炎性CD4+T细胞谱系,参与了过敏性鼻炎(AR)的病理生理过程。IL-35主要由自然调节性T细胞(Treg)(nTreg)分泌,且依赖于Foxp3的表达,能够有效的减弱过敏原诱导的特异性气道炎症。然

盘点:鼻炎治疗研究盘点

【1】Auris Nasus Larynx:氟替卡松丙酸酯对人类鼻纤维母细胞的影响研究 颗粒物质(PM)包含了有机化合物和毒性金属,是空气污染的主要原因。PM能够进入身体,引起各种健康问题。尽管PM对下呼吸道的影响已有很多研究,但是对上呼吸道(包括鼻腔)的影响仍旧需要进一步的评估。最近,有研究人员调查了氟替卡松丙酸酯(FP)接触城市颗粒物(UPM)鼻纤维母细胞的影响。研究人员从6